Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilpisertib in Moderately to Severely Active Ulcerative Colitis
NCT04130919Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of tilpisertib in ulcerative colitis (UC) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants Who Achieved Clinical Remission Per Modified Mayo Clinic Score (MCS) at 10 weeks. Started Dec 2019; status: terminated.
02
Drugs
tilpisertib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04130919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130919.